Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) underperformed in 2025. Each firms encountered some points, a few of which can linger all through this yr.
Nonetheless, these drugmakers nonetheless have lots to supply. And given their underperformance over the trailing 12 months, now is perhaps a very good time to purchase their shares, particularly as each commerce beneath $40. This is why Pfizer and Viking Therapeutics are enticing shares to purchase proper now.
In equity, Pfizer did not simply carry out poorly in 2025. The previous three years have been difficult for the pharmaceutical large. However there’s a mild on the finish of the tunnel. Pfizer is making strikes that ought to permit it to enhance its monetary outcomes down the road and overcome upcoming patent cliffs. The corporate has began operating medical trials, together with late-stage research, for a promising most cancers drugs referred to as PF-4404. Administration sees this as a possible pipeline of medicine that can safe approvals throughout a number of types of most cancers.
Pfizer can be making strides within the weight administration market. It now owns one of many extra promising mid-stage property on this space, MET-097i, following an acquisition it closed final yr. These two candidates, PF-4404 and MET-097i, are solely the tip of the iceberg.
The drug large has a deep pipeline with merchandise spanning oncology, immunology, vaccines, and extra. Over the following a number of years, the drugmaker ought to earn at the very least just a few necessary approvals. Additional, the corporate has addressed a big risk, that of tariffs, by signing a take care of the White Home that can make it exempt from duties on imports for 3 years in alternate for promoting some medicines at diminished costs within the U.S.
Pfizer could not rebound this yr, however at present ranges, the inventory seems to be enticing for buyers keen to remain the course. Over the following 10 years, the pharmaceutical large may ship superior returns.
Viking Therapeutics is a riskier inventory. The corporate is a clinical-stage biotech — it at present has no product available on the market. Nonetheless, Viking’s main candidate, VK2735, seems to be a promising weight-loss drugs. It’s at present being investigated in section 3 research in a subcutaneous formulation. Viking can be creating an oral model of VK2735, which is in mid-stage trials.
